First Generic Exclusivity May Not Be Necessary For Competition - FTC Staffer

Elimination of the 180-day "first generic" exclusivity provision in the Waxman/Hatch Act may not be harmful to competition, Federal Trade Commission Bureau of Competition Assistant Director for Policy & Evaluation David Balto told the Food & Drug Law Institute annual meeting in Washington, D.C. Dec. 17.